Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere's Q1 Revenues, Loss Rise

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nanosphere today reported that its first-quarter 2010 revenues more than tripled year over year but were flat sequentially.

The Northbrook, Ill.-based molecular diagnostics firm brought in total revenues of $825,827 for the three months ended March 31, compared to $255,225 for the first quarter of 2009. However, its revenues were flat from Q4 2009. Analysts, on average, had expected revenues of $1.4 million.

Nanosphere's net loss increased 5 percent to $8.6 million, or $.31 per share, from $8.2 million, or $.37 per share. It matched analysts' consensus estimate for the bottom line.

The firm's R&D spending declined 8 percent to $4.4 million from $4.8 million. Nanosphere said the reduced R&D expenses were due to "completion of prototype material investments" for its Verigene SP molecular diagnostics instrument.

Its SG&A spending jumped 32 percent to $4.1 million from $3.1 million, partially due to a $700,000 increase in non-cash share-based compensation.

Nanosphere finished the quarter with $67.3 million in cash and cash equivalents.

"We continue to make progress expanding the Verigene System test menu for infectious disease, human genetics, pharmacogenetics, and protein assays," Nanosphere President and CEO William Moffitt said. "These tests will increase the applicability of the Verigene System and will generate increased customer placements and utilization."

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.